BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Language Learning Stages: Which One Gets Your Vote? - 2‘Integral part of our nation’: Herzog visits Franciscan Sisters in Jerusalem ahead of Christmas
- 3The Most Astonishing Arising Advances to Watch
- 4Spots To Go Birdwatching All over the Planet
- 5Vote In favor of Your Favored Video Conferencing Administration
- Fossil analysis changes what paleontologists know about how long T. rex took to grow full size
- Inconceivable Spots To Stargaze All over The Planet
- Abbott issues US device correction for some glucose monitors over faulty readings risk
- Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
- An Extended period of Voyaging Carefully: the World with Reason
- Keep It Cool: Uncovering Famous Fridge Brands for Each Home
- Portable Installment Answers for Independent ventures
- Instructions to Warmly greet Discretion and Thoughtfulness
- World leaders, rights groups react to COP30 climate deal
